Seasonal vaccine approval is routine and expected after the EMA ETF recommendation. Monitor EU member state procurement decisions and reimbursement terms for the 2026-2027 season to gauge revenue contribution. Also watch for FDA and other regulatory decisions on the updated formula in other key markets.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $92.85entry
- T+1 · 4mo ago −2.44%α −3.15% · $90.58
- T+5 · 3mo ago −1.79%α −5.41% · $91.19
- T+20 · 3mo ago +19.98%α +16.01% · $111.40
- T+60 · 25d ago −5.10%α −7.56% · $88.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech (BNTX) announced via 6-K that the European Commission has granted marketing authorization for its 2026-2027 COVID-19 vaccine formula targeting the XFG variant. The approval, valid across the EU plus Iceland, Liechtenstein, and Norway, allows BioNTech and Pfizer to supply the updated monovalent vaccine ahead of the respiratory season. Manufacturing at risk has already commenced, but no financial terms or revenue impact were disclosed.
Key Facts
- European Commission authorized the 2026-2027 XFG-adapted COVID-19 vaccine for individuals 6 months and older.
- Authorization is valid in all 27 EU member states, Iceland, Liechtenstein, and Norway.
- Manufacturing at risk has been initiated by Pfizer and BioNTech to ensure supply readiness.
- More than 5 billion doses of the Pfizer-BioNTech COVID-19 vaccines have been distributed globally.
- No financial figures (revenue, deal value, or guidance) were provided in the filing.
Financial Impact
Regulatory approval for seasonal vaccine update; no financial terms or revenue figures disclosed.
Risk Factors
- Demand for COVID-19 vaccines may decline further as the pandemic transitions to endemic phase.
- Competition from other vaccine developers targeting the same variant could limit market share.
- Evolving viral variants may reduce efficacy of the XFG-adapted vaccine before the season ends.
- Pricing pressure from government procurement could compress margins.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000047 |
| Document: form6-kxfgvariantvaccineec.htm | 0001776985-26-000047 |
| Document: 0001776985-26-000047-index-headers.html | 0001776985-26-000047 |
| Document: 0001776985-26-000047-index.html | 0001776985-26-000047 |
| Document: 0001776985-26-000047.txt | 0001776985-26-000047 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers